Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica

Journal of Neuroimmunology

Volumn 254, Issue 1-2, 2013, Pages 178-182

  Kuroda, Hiroshi ^a   Fujihara, Kazuo ^a   Takano, Rina ^a   Takai, Yoshiki ^a   Takahashi, Toshiyuki ^b   Misu, Tatsuro ^a   Nakashima, Ichiro ^a   Sato, Shigeru ^c   Itoyama, Yasuto ^a,d   Aoki, Masashi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yonezawa National Hospital   (Japan)

^c Kohnan Hospintal ^*  (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Anaphylatoxins; C5a; Cerebrospinal fluid; Complement; Neuromyelitis optica; Relapse

Indexed keywords

COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A;

ADOLESCENT; AGED; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BRAIN; COMPLEMENT C5A; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; NEUROMYELITIS OPTICA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84871683149     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.09.002     Document Type: Article

References (18)

1. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
2. Doi H., Matsushita T., Isobe N., Matsuoka T., Minohara M., Ochi H., Kira J. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult. Scler. 2008, 15:304-310.
3. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., Kryzer T.J., Lennon V.A. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
4. Kinoshita M., Nakatsuji Y., Moriya M., Okuno T., Kumanogoh A., Nakano M., Takahashi T., Fujihara K., Tanaka K., Sakoda S. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009, 20:508-512.
5. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
6. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
7. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
8. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
9. Manthey H.D., Woodruff T.M., Taylor S.M., Monk P.N. Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 2009, 41:2114-2117.
10. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., Takahashi T., Nakashima I., Takahashi H., Itoyama Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
11. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009, 373:759-767.
12. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
13. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
14. Sabater L., Giralt A., Boronat A., Hankiewicz K., Blanco Y., Llufriu S., Alberch J., Graus F., Saiz A. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J. Neuroimmunol. 2009, 215:31-35.
15. Smith J.G. Vasculitis. J. Dermatol. 1995, 22:812-822.
16. Spronk P.E., Limburg P.C., Kallenberg C.G. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995, 4:86-94.
17. Tuzun E., Kurtuncu M., Turkoglu R., Icoz S., Pehlivan M., Birisik O., Eraksoy M., Akman-Demir G. Enhanced complement consumption in neuromyelitis optica and Behcet's disease patients. J. Neuroimmunol. 2011, 233:211-215.
18. Uzawa A., Mori M., Arai K., Sato Y., Hayakawa S., Masuda S., Taniguchi J., Kuwabara S. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult. Scler. 2010, 16:1443-1452.